Cargando…
Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study
Hypernatremia (>145 mmol/L) is a relatively rare event, and the data regarding its role in the outcome of inpatients on an oncology ward are weak. The aim of this study was to describe the prevalence, prognosis, and outcome of hospitalized cancer patients with hypernatremia. We performed a retros...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689174/ https://www.ncbi.nlm.nih.gov/pubmed/36421346 http://dx.doi.org/10.3390/curroncol29110693 |
_version_ | 1784836463597191168 |
---|---|
author | del Rio, Jessica Buess, Martin |
author_facet | del Rio, Jessica Buess, Martin |
author_sort | del Rio, Jessica |
collection | PubMed |
description | Hypernatremia (>145 mmol/L) is a relatively rare event, and the data regarding its role in the outcome of inpatients on an oncology ward are weak. The aim of this study was to describe the prevalence, prognosis, and outcome of hospitalized cancer patients with hypernatremia. We performed a retrospective case-control study of data obtained from inpatients with a solid tumor at the St. Claraspital, Basel, Switzerland, who were admitted between 2017 and 2020. The primary endpoint was overall survival. Hypernatremia was found in 93 (3.16%) of 2945 inpatients bearing cancer or lymphoma. From 991 eligible normonatremic control patients, 93 were matched according to diagnosis, age, and sex. The median overall survival time (OS) of patients with hypernatremia was 1.5 months compared to 11.7 months of the normonatremic controls (HR 2.69, 95% CI 1.85–3.90, p < 0.0001). OS of patients with irreversible compared to reversible hypernatremia was significantly shorter (23 versus 88 days, HR 4.0, 95% CI 2.04–7.70, p < 0.0001). The length of hospital stay was significantly longer for the hypernatremic than for the normonatremic group (p < 0.0001). Significantly more patients with hypernatremia died in the hospital (30.1% versus 8.6%, p < 0.001). These results suggest hypernatremia to be associated with an unfavorable outcome and a very short OS. |
format | Online Article Text |
id | pubmed-9689174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96891742022-11-25 Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study del Rio, Jessica Buess, Martin Curr Oncol Article Hypernatremia (>145 mmol/L) is a relatively rare event, and the data regarding its role in the outcome of inpatients on an oncology ward are weak. The aim of this study was to describe the prevalence, prognosis, and outcome of hospitalized cancer patients with hypernatremia. We performed a retrospective case-control study of data obtained from inpatients with a solid tumor at the St. Claraspital, Basel, Switzerland, who were admitted between 2017 and 2020. The primary endpoint was overall survival. Hypernatremia was found in 93 (3.16%) of 2945 inpatients bearing cancer or lymphoma. From 991 eligible normonatremic control patients, 93 were matched according to diagnosis, age, and sex. The median overall survival time (OS) of patients with hypernatremia was 1.5 months compared to 11.7 months of the normonatremic controls (HR 2.69, 95% CI 1.85–3.90, p < 0.0001). OS of patients with irreversible compared to reversible hypernatremia was significantly shorter (23 versus 88 days, HR 4.0, 95% CI 2.04–7.70, p < 0.0001). The length of hospital stay was significantly longer for the hypernatremic than for the normonatremic group (p < 0.0001). Significantly more patients with hypernatremia died in the hospital (30.1% versus 8.6%, p < 0.001). These results suggest hypernatremia to be associated with an unfavorable outcome and a very short OS. MDPI 2022-11-16 /pmc/articles/PMC9689174/ /pubmed/36421346 http://dx.doi.org/10.3390/curroncol29110693 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article del Rio, Jessica Buess, Martin Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study |
title | Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study |
title_full | Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study |
title_fullStr | Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study |
title_full_unstemmed | Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study |
title_short | Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study |
title_sort | outcome of hospitalized cancer patients with hypernatremia: a retrospective case-control study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689174/ https://www.ncbi.nlm.nih.gov/pubmed/36421346 http://dx.doi.org/10.3390/curroncol29110693 |
work_keys_str_mv | AT delriojessica outcomeofhospitalizedcancerpatientswithhypernatremiaaretrospectivecasecontrolstudy AT buessmartin outcomeofhospitalizedcancerpatientswithhypernatremiaaretrospectivecasecontrolstudy |